Fig. 5.

α-GalCer protects mice from spontaneous sarcoma. The appearance of tumors was recorded in groups of 34–35 B6 p53^–/– mice receiving either vehicle or 2 μgof α-GalCer i.p. weekly from 4 weeks of age. Mice were evaluated on a weekly basis. When mice were moribund, tumor type (open squares, thymic lymphoma; filled triangles, disseminated lymphoma; open circles, sarcoma; filled diamonds, other tumors) was recorded against the age (in days) at the time of death/autopsy. The mean age of p53^–/– mice developing spontaneous sarcoma is depicted by the cross bars, and the statistically later incidences of sarcomas in the α-GalCer-treated group were noted (192.6 ± 6.1 days), compared with vehicle-treated mice (147.1 ± 8.3 days; P = 0.0005, Mann–Whitney U test).